Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
30 March, 2017 14:21 IST
Divis Lab receives import alert for Visakhapatnam facility
Source: IRIS | 21 Mar, 2017, 10.10AM
Comments  |  Post Comment

Divis Laboratories, a pharmaceutical ingredients and intermediates company, has received an Import Alert 66-40 from US Food and Drug Administration (USFDA) for its products manufactured at the company's Unit-II located at Visakhapatnam, Andhra Pradesh on March 20, 2017.

The agency has exempted the following products from the Import Alert-Levetiracetam, Gabapentin, Lamotrigine, Capecitabine, Naproxen sodium, Raltegravir potassium, Atovaquone, Chloropurine, BOC core succinate, 2, 4-wing active ester.

The company along with third party consultants is currently working to address the concerns of the USFDA and is making all efforts to fully meet the compliance requirements. 

Shares of the company declined Rs 138.7, or 17.54%, to trade at Rs 652.00. The total volume of shares traded was 1,228,420 at the BSE (10.02 a.m., Tuesday).



Divis Laboratories Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Sector
Crude oil price of Indian basket rises 1.6% - 30-Mar-2017 14:09
Aurobindo Pharma receives USFDA approval for Generic Epzicom tablets - 30-Mar-2017 13:58
Kellton Tech acquires Lenmar Group of Companies - 30-Mar-2017 13:53
L&T Construction wins orders worth Rs 17.25 bn - 30-Mar-2017 13:50
BHEL commissions 800 MW Supercritical Thermal Power Plant in Karnataka - 30-Mar-2017 13:47
Union Bank of India issues Tier I Bonds aggregating Rs 2.50 bn - 30-Mar-2017 13:45
Ujaas Energy to divest entire holding in Ujaas Energy HK - 30-Mar-2017 13:42
Future Lifestyle sets up arm; looks to monetise brands - 30-Mar-2017 13:40
Berger Paints India commences production at Nalbari plant - 30-Mar-2017 13:34
Glenmark Pharmaceuticals reports positive results from phase 3 trial of GSP 301 - 30-Mar-2017 13:32
Sadbhav Engineering inks EPC agreement with Sadbhav Bangalore Highway - 30-Mar-2017 13:29
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer